Table 1 Characteristics of included studies
Author | Years | Follow-up | Intervention (mg) | Comparator | Age | Female (%) | BMI | Duration | Outcome |
|---|---|---|---|---|---|---|---|---|---|
Pujalte JM | 1980 | 8Â weeks | GS (1,500) | Placebo | 61.7 | 85 | - | - | VAS, AR |
Lopes VA | 1982 | 8Â weeks | GS (1,500) | NSAIDs | 56.4 | 74 | - | 3.2 | VAS, AR |
Muller FH | 1994 | 4Â weeks | GS (1,500) | NSAIDs | 54 | 42.3 | - | 4.8 | Lequesne, AR |
Noack W | 1994 | 4Â weeks | GS (1,500) | Placebo | 55 | 60.3 | - | - | Lequesne, AR |
Nguyen M | 1994 | 8Â weeks | D (50) | NSAIDs, placebo | 62 | 62.7 | - | 5.25 | VAS, Lequesne, AR |
Qiu GX | 1998 | 4Â weeks | GS (1,500) | NSAIDs | 56.4 | 79 | - | - | VAS, AR |
Houpt JB | 1999 | 8Â weeks | GH (1,500) | Placebo | 64.5 | 64.4 | - | 8.3 | WOMAC, AR |
Rindone JP | 2000 | 4, 8Â weeks | GS (1,500) | Placebo | 63.5 | 5.1 | - | 13 | VAS, AR |
Pelletier JP | 2000 | 24Â weeks | D (50, 100, 150) | Placebo | 62.8 | 76 | 31.28 | 7.9 | VAS |
Reginster JY | 2001 | 3Â years | GS (1,500) | Placebo | 65.8 | 79.4 | 27.35 | 7.8 | WOMAC, JSW, AR |
Dougados M | 2001 | 3Â years | D (100) | Placebo | 62.6 | 84 | - | - | Lequesne, JSW |
Hughes R | 2002 | 6Â months | GS (1,500) | Placebo | 62.3 | 68 | - | 7.63 | AR |
Pavelka K | 2002 | 1, 2, 3Â years | GS (1,500) | Placebo | 62.4 | 78.5 | 25.7 | 10.55 | Lequesne, JSW, AR |
Braham R | 2003 | 3Â months | GS (2,000) | Placebo | 42.2 | 28.3 | - | 12.97 | AR |
Cibere J | 2004 | 24Â weeks | GS (1,500) | Placebo | 64.5 | 57.7 | 25.26 | 1.6 | AR |
McAlindon T | 2004 | 12Â weeks | GS (1,500) | Placebo | - | 64 | 32.57 | - | WOMAC, AR |
Pham T | 2004 | 1Â year | D (100) | Placebo | 64.7 | 65.3 | 29.6 | - | Lequesne |
Clegg DO | 2006 | 24Â weeks | GS (1,500) | Placebo, NSAIDs | 58.7 | 42.2 | 31.73 | 10 | WOMAC, AR |
Zheng WJ | 2006 | 12, 16Â weeks | D (100) | NSAIDs | 56.2 | 66.2 | 26.13 | 7.23 | VAS, WOMAC, AR |
Herrero-Beaumont G | 2007 | 24Â weeks | GS (1,500) | Placebo | 63.9 | 88 | 27.65 | 7.31 | Lequesne, AR |
Louthrenoo W | 2007 | 12, 24Â weeks | D (50) | NSAIDs | 54 | 73 | 26.85 | 3.58 | WOMAC |
Pavelka K | 2007 | 12, 24Â weeks | D (50) | Placebo | 63.7 | 65.5 | 28.9 | 6.497 | WOMAC, AR |
Frestedt JL | 2008 | 12Â weeks | GS (1,500) | Placebo | 59.1 | 60 | 32.24 | - | WOMAC, AR |
Kawasaki T | 2008 | 18Â weeks | GS (1,500) | Placebo | 68.9 | - | 23.95 | - | JSW |
Rozendaal RM | 2008 | 3, 12, 24Â months | GS (1,500) | Placebo | 63.4 | 69.4 | 27.95 | - | JSW, AR |
Sawitzke AD | 2008 | 2Â months | GS (1,500) | Placebo, NSAIDs | 50.6 | 55.7 | - | 8.52 | JSW |
Brahmachari B | 2009 | 12Â weeks | D (50) | Placebo | 49.1 | 83.6 | 24.66 | 2.76 | VAS, WOMAC, AR |
Madhu K | 2013 | 6Â weeks | GS (1,500) | Placebo | 56.8 | 70 | 27.9 | - | VAS, AR |
Chopra A | 2013 | 24Â weeks | GS (1,500) | NSAIDs | 55.5 | - | 27.7 | - | WOMAC, AR |
Durmus D | 2013 | 12Â weeks | GS (1,500) | Placebo | 55.8 | - | 27.7 | - | WOMAC |
Kwoh CK | 2014 | 24Â weeks | GS (1,500) | Placebo | 52.24 | 48.9 | 28.9 | - | WOMAC, AR |